Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11780474 | 0.86 | GAA (0.55) | RAB9ASMN1; SMN2GAAJAK2TYK2 | |
| SCHEMBL11780084 | 0.84 | LMNA (0.58) | NPC1RAB9ASMN1; SMN2HDAC6MEN1 | |
| SCHEMBL3759860 | 0.83 | HPGDS (0.47) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL11783362 | 0.83 | RAB9A (0.55) | NPC1RAB9ASMN1; SMN2PKMGAA | |
| SCHEMBL11781086 | 0.83 | FFAR2 (0.57) | NPC1RAB9ASMN1; SMN2GAAHPGDS | |
| SCHEMBL18132556 | 0.82 | KMT2A (0.56) | PKMMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7347368 | 0.82 | HPGDS (0.46) | NPC1RAB9ASMN1; SMN2HPGDSMEN1 | |
| SCHEMBL8556879 | 0.82 | NT5E (0.57) | NPC1RAB9ASMN1; SMN2HPGDSHDAC6 | |
| SCHEMBL8125790 | 0.82 | HPGDS (0.44) | NPC1RAB9ASMN1; SMN2PKMMAOB | |
| SCHEMBL11783568 | 0.82 | HPGDS (0.58) | NPC1RAB9AGAAHPGDSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | claimed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| CN-114466844-B | N- (1H-imidazol-2-yl) benzamide compound and pharmaceutical composition comprising same as active ingredient | 康佳诺医疗科技发展有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-114466844-B | N- (1H-imidazol-2-yl) benzamide compound and pharmaceutical composition comprising same as active ingredient | 康佳诺医疗科技发展有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-114466844-B | N- (1H-imidazol-2-yl) benzamide compound and pharmaceutical composition comprising same as active ingredient | 康佳诺医疗科技发展有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250041291-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EMMAUS LIFE SCIENCES INC (US) | 2025-02-06 | — | — | US | disclosed |
| US-20250041291-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EMMAUS LIFE SCIENCES INC (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4444716-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Kainos Medicine, Inc. (KR) | 2024-10-16 | — | — | EP | disclosed |
| CN-114466844-A | N- (1H-imidazol-2-yl) benzamide compounds and pharmaceutical compositions containing the same as active ingredient | 康佳诺医疗科技发展有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114466844-A | N- (1H-imidazol-2-yl) benzamide compounds and pharmaceutical compositions containing the same as active ingredient | 康佳诺医疗科技发展有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114466844-A | N- (1H-imidazol-2-yl) benzamide compounds and pharmaceutical compositions containing the same as active ingredient | 康佳诺医疗科技发展有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2021066559-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021066559-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2021-04-08 | — | — | WO | disclosed |
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2004089877-A1 | NEW HYDROXYNAPHTHYL AMIDES | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
| EP-0283857-B1 | BENZYLIDENAMINO, BENZYLAMINO AND BENZOYLAMINO IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| EP-0283857-A1 | Benzylidenamino, benzylamino and benzoylamino imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-09-28 | — | — | EP | disclosed |
| US-3979404-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041291-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BTK, PARP1, PARP2 | NPC1 4588/4885RAB9A 4490/4885SMN1; SMN2 2950/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | NPC1 880/4885RAB9A 2924/4885SMN1; SMN2 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.